Enzymotec Ltd. Announces Publication Acceptance of Clinical Study Results on Usage of Vayacog(R) in Non-Demented Elderly

        Print
| Source: Enzymotec Ltd.

MIGDAL HA'EMEQ, Israel, Dec. 9, 2013 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-functional lipid ingredients, announced today the acceptance for future publication of its clinical study results evaluating the safety and effectiveness of Vayacog® usage in non-demented elderly.

The article manuscript titled "Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: Results from an open-label extension" was accepted for publication in the peer-reviewed journal "Dementia and Geriatric Cognitive Disorders." The study was conducted by Professor Amos Korczyn from Sourasky Medical Center, Department of Neurology, Tel-Aviv, Israel.

Enzymotec's 15-week study was an extension of a previously published study in 2010. This extension aimed to evaluate the effect of Vayacog® (one capsule/day) on cognitive performance of 122 non-demented elderly participants with memory complaints. Efficacy was assessed using a computerized tool and the Clinical Global Impression of Change (CGI-C) rating scale.

During the study, a significant improvement (p0.05 > ) in sustained attention and memory recognition was observed in subjects switching from placebo to Vayacog® (naïve group). Additionally, a significant improvement in CGI-C was observed in this group.

"We are very pleased with the results of the study, which further demonstrated the positive effects of consumption of Vayacog® for dietary management of early memory impairment in elderly patients," said Dr. Ariel Katz, President and Chief Executive Officer of Enzymotec Ltd.

"The results are noteworthy because no drug is available that can ameliorate cognitive state in normal elderly people complaining of memory impairment," said Professor Amos Korczyn, the principal investigator of this study.

Vayacog® is an orally administered prescription medical food for the clinical dietary management of certain lipid imbalances associated with early memory impairment.

About Enzymotec Ltd.

Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-functional lipid ingredients, as well as final products, based on sophisticated processes and technologies.

Forward Looking Statement

This release may contain forward-looking statements, which express the current beliefs and expectations of Company management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences the following risks: a high proportion of the sales of our InFat product is sold to end users by a single company in China; we rely on our Swedish joint venture partner to manufacture InFat, and certain matters related to the joint venture are or, based on communications from our joint venture partner, are the subject of disagreement; our gross profits may be adversely affected if we are only able to obtain lower quality krill meal; our ability to obtain krill may be affected by conservation regulation or initiatives; we are dependent on a single facility that houses the majority of our operations; we may not be able to expand our production or processing capabilities or satisfy growing demand; our product development cycle is lengthy and uncertain, and our development or commercialization efforts for our products may be unsuccessful; we are subject to significant and increasing government regulations regarding the sale and marketing of our products; we may not be able to protect our proprietary technology or prevent its unauthorized use by third parties; we are currently subject to litigation, and in the future may become subject to additional litigation, regarding intellectual property rights; and other factors discussed under the heading "Risk Factors" in the Company's final prospectus for its initial public offering filed with the Securities and Exchange Commission on September 30, 2013. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

ICR, LLC
Katie Turner
646-277-1228


-or-

John Mills
310-954-1105